Barclays’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-16,745
| Closed | -$81K | – | 6545 |
|
|
2020
Q1 | $81K | Sell |
16,745
-30,946
| -65% | -$201K | ﹤0.01% | 4941 |
|
|
2019
Q4 | $507K | Buy |
47,691
+23,905
| +101% | +$237K | ﹤0.01% | 4290 |
|
|
2019
Q3 | $248K | Sell |
23,786
-2,153
| -8% | -$28.2K | ﹤0.01% | 4814 |
|
|
2019
Q2 | $398K | Buy |
25,939
+13,859
| +115% | +$200K | ﹤0.01% | 4537 |
|
|
2019
Q1 | $155K | Sell |
12,080
-28,013
| -70% | -$317K | ﹤0.01% | 5024 |
|
|
2018
Q4 | $381K | Buy |
40,093
+24,497
| +157% | +$318K | ﹤0.01% | 4060 |
|
|
2018
Q3 | $258K | Sell |
15,596
-2,266
| -13% | -$36.3K | ﹤0.01% | 4800 |
|
|
2018
Q2 | $286K | Sell |
17,862
-5,561
| -24% | -$99.3K | ﹤0.01% | 4423 |
|
|
2018
Q1 | $358K | Buy |
23,423
+10,254
| +78% | +$160K | ﹤0.01% | 4295 |
|
|
2017
Q4 | $206K | Sell |
13,169
-5,241
| -28% | -$70.1K | ﹤0.01% | 4670 |
|
|
2017
Q3 | $204K | Buy |
18,410
+16,793
| +1,039% | +$158K | ﹤0.01% | 4409 |
|
|
2017
Q2 | $15K | Sell |
1,617
-975
| -38% | -$8.13K | ﹤0.01% | 5926 |
|
|
2017
Q1 | $22K | Buy |
2,592
+957
| +59% | +$8.72K | ﹤0.01% | 5774 |
|
|
2016
Q4 | $18K | Buy |
1,635
+142
| +10% | +$1.72K | ﹤0.01% | 5687 |
|
|
2016
Q3 | $16K | Buy |
1,493
+106
| +8% | +$862 | ﹤0.01% | 5595 |
|
|
2016
Q2 | $9K | Buy |
+1,387
| New | +$8.76K | ﹤0.01% | 5594 |
|
|
2015
Q4 | – | Sell |
-82
| Closed | -$1K | – | 6849 |
|
|
2015
Q3 | $1K | Sell |
82
-217
| -73% | -$2.28K | ﹤0.01% | 6680 |
|
|
2015
Q2 | $3K | Sell |
299
-152
| -34% | -$2.11K | ﹤0.01% | 6726 |
|
|
2015
Q1 | $7K | Sell |
451
-487
| -52% | -$7.45K | ﹤0.01% | 6471 |
|
|
2014
Q4 | $16K | Sell |
938
-1,998
| -68% | -$28.8K | ﹤0.01% | 6456 |
|
|
2014
Q3 | $35K | Buy |
2,936
+2,740
| +1,398% | +$33.7K | ﹤0.01% | 6135 |
|
|
2014
Q2 | $3K | Sell |
196
-2,570
| -93% | -$39.4K | ﹤0.01% | 7327 |
|
|
2014
Q1 | $55K | Sell |
2,766
-7,080
| -72% | -$172K | ﹤0.01% | 5924 |
|
|
2013
Q4 | $187K | Buy |
9,846
+9,504
| +2,779% | +$254K | ﹤0.01% | 5074 |
|
|
2013
Q3 | $15K | Sell |
342
-139
| -29% | -$4.53K | ﹤0.01% | 6654 |
|
|
2013
Q2 | $11K | Buy |
+481
| New | +$7.66K | ﹤0.01% | 7114 |
|
Barclays's STML Position: Q2 2020 in Review
Barclays sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 16,745 shares — an estimated $81K sold.
Barclays first reported a position in STML in Q2 2013 and held it in 26 quarters. The position peaked at $507K in Q4 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Barclays reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Barclays sold 16,745 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $81K.
- Barclays first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 26 quarters.
- Barclays's Stemline Therapeutics, Inc. position peaked at $507K in Q4 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Barclays's 13F filing for Q2 2020, filed 12 Aug 2020.